Dupont Capital Management Corp purchased a new stake in Sangamo Therapeutics Inc (NASDAQ:SGMO) in the third quarter, Holdings Channel reports. The firm purchased 31,844 shares of the biopharmaceutical company’s stock, valued at approximately $288,000.
Other hedge funds and other institutional investors have also recently modified their holdings of the company. First Manhattan Co. bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $32,000. Steward Partners Investment Advisory LLC bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $50,000. Tiverton Asset Management LLC bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $79,000. McGuire Investment Group LLC bought a new stake in shares of Sangamo Therapeutics in the 3rd quarter valued at approximately $110,000. Finally, Quantitative Systematic Strategies LLC bought a new stake in shares of Sangamo Therapeutics in the 2nd quarter valued at approximately $126,000. Institutional investors and hedge funds own 69.23% of the company’s stock.
NASDAQ:SGMO opened at $9.85 on Friday. Sangamo Therapeutics Inc has a 12-month low of $6.26 and a 12-month high of $13.91. The firm has a market capitalization of $1.09 billion, a P/E ratio of -14.07 and a beta of 2.79. The business has a 50 day simple moving average of $9.03 and a 200 day simple moving average of $10.37.
Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Wednesday, November 6th. The biopharmaceutical company reported ($0.24) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.10. Sangamo Therapeutics had a negative return on equity of 27.32% and a negative net margin of 136.73%. The business had revenue of $21.96 million during the quarter, compared to analyst estimates of $12.16 million. During the same quarter in the previous year, the firm posted ($0.13) EPS. The business’s revenue for the quarter was down 6.8% compared to the same quarter last year. As a group, sell-side analysts forecast that Sangamo Therapeutics Inc will post -1.32 EPS for the current fiscal year.
SGMO has been the subject of a number of research analyst reports. HC Wainwright initiated coverage on Sangamo Therapeutics in a report on Monday, August 26th. They issued a “buy” rating and a $16.00 price target for the company. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a report on Wednesday, July 17th. ValuEngine upgraded Sangamo Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 1st. Finally, BidaskClub upgraded Sangamo Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Wednesday, October 30th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating, one has given a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $14.00.
Sangamo Therapeutics Company Profile
Sangamo Therapeutics, Inc focuses on translating science into genomic medicines that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression or gene regulation.
Read More: Management Fee
Want to see what other hedge funds are holding SGMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sangamo Therapeutics Inc (NASDAQ:SGMO).
Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.